BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 33508821)

  • 1. Dual-Tracer (68Ga-DOTATOC and 18F-FDG-)-PET/CT Scan and G1-G2 Nonfunctioning Pancreatic Neuroendocrine Tumors: A Single-Center Retrospective Evaluation of 124 Nonmetastatic Resected Cases.
    Paiella S; Landoni L; Tebaldi S; Zuffante M; Salgarello M; Cingarlini S; D'Onofrio M; Parisi A; Deiro G; Manfrin E; Bianchi B; Montagnini G; Crinò SF; Bassi C; Salvia R
    Neuroendocrinology; 2022; 112(2):143-152. PubMed ID: 33508821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Combined 68Ga-DOTATOC and 18F-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors: Implications for Managing Surgical Decisions.
    Cingarlini S; Ortolani S; Salgarello M; Butturini G; Malpaga A; Malfatti V; DʼOnofrio M; Davì MV; Vallerio P; Ruzzenente A; Capelli P; Citton E; Grego E; Trentin C; De Robertis R; Scarpa A; Bassi C; Tortora G
    Pancreas; 2017 Jan; 46(1):42-47. PubMed ID: 27906872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual tracer 68Ga-DOTATOC and 18F-FDG PET/computed tomography radiomics in pancreatic neuroendocrine neoplasms: an endearing tool for preoperative risk assessment.
    Mapelli P; Partelli S; Salgarello M; Doraku J; Pasetto S; Rancoita PMV; Muffatti F; Bettinardi V; Presotto L; Andreasi V; Gianolli L; Picchio M; Falconi M
    Nucl Med Commun; 2020 Sep; 41(9):896-905. PubMed ID: 32796478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 68Ga-DOTATOC and 18F-FDG PET/CT for identifying the primary lesions of suspected and metastatic neuroendocrine tumors: A prospective study in Taiwan.
    Chen SH; Chang YC; Hwang TL; Chen JS; Chou WC; Hsieh CH; Yeh TS; Hsu JT; Yeh CN; Tseng JH; Chen TC; Yen TC
    J Formos Med Assoc; 2018 Jun; 117(6):480-487. PubMed ID: 28735662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual Tracer 68Ga-DOTATOC and 18F-FDG PET Improve Preoperative Evaluation of Aggressiveness in Resectable Pancreatic Neuroendocrine Neoplasms.
    Mapelli P; Partelli S; Salgarello M; Doraku J; Muffatti F; Schiavo Lena M; Pasetto S; Bezzi C; Bettinardi V; Andreasi V; Rancoita PMV; Gianolli L; Picchio M; Falconi M
    Diagnostics (Basel); 2021 Jan; 11(2):. PubMed ID: 33525712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of 68Ga-DOTANOC and 18F-FDG PET-CT Scans in the Evaluation of Primary Tumors and Lymph Node Metastasis in Patients With Rectal Neuroendocrine Tumors.
    Zhou Z; Wang Z; Zhang B; Wu Y; Li G; Wang Z
    Front Endocrinol (Lausanne); 2021; 12():727327. PubMed ID: 34539577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastasis From Clear Cell Renal Cell Carcinoma Mimicking Well-Differentiated Pancreatic Neuroendocrine Tumor at 18F-FDG and 68Ga-DOTATOC PET/CT.
    Guglielmo P; Pesella F; Sartorello A; El Khouzai B; Berti S; Muccioli S; Gregianin M
    Clin Nucl Med; 2022 Jul; 47(7):e498-e499. PubMed ID: 35675141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic performances of 68Ga-DOTATOC versus 18Fluorodeoxyglucose positron emission tomography in pulmonary carcinoid tumours and interrelationship with histological features.
    Lococo F; Rapicetta C; Mengoli MC; Filice A; Paci M; Di Stefano T; Coruzzi C; Versari A
    Interact Cardiovasc Thorac Surg; 2019 Jun; 28(6):957-960. PubMed ID: 30753507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-FDG PET/CT and 68Ga-DOTATOC PET/CT in Diffuse Pancreatic Neuroendocrine Tumor.
    Ji X; Dong A; He Q; Dong H; Zuo C
    Clin Nucl Med; 2020 May; 45(5):e245-e248. PubMed ID: 32049733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.
    Koukouraki S; Strauss LG; Georgoulias V; Eisenhut M; Haberkorn U; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1115-22. PubMed ID: 16763820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the role of [18F]FDG-PET/CT and [68Ga]DOTATOC-PET/CT in differentiating typical and atypical pulmonary carcinoids.
    Jindal T; Kumar A; Venkitaraman B; Meena M; Kumar R; Malhotra A; Dutta R
    Cancer Imaging; 2011 Jun; 11(1):70-5. PubMed ID: 21697027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter comparison of 18F-FDG and 68Ga-DOTA-peptide PET/CT for pulmonary carcinoid.
    Lococo F; Perotti G; Cardillo G; De Waure C; Filice A; Graziano P; Rossi G; Sgarbi G; Stefanelli A; Giordano A; Granone P; Rindi G; Versari A; Rufini V
    Clin Nucl Med; 2015 Mar; 40(3):e183-9. PubMed ID: 25608152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative characterization of indeterminate large adrenal masses with dual tracer PET-CT using fluorine-18 fluorodeoxyglucose and gallium-68-DOTANOC: initial results.
    Naswa N; Sharma P; Soundararajan R; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
    Diagn Interv Radiol; 2013; 19(4):294-8. PubMed ID: 23439252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
    Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
    J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of 18F-DOPA Versus 68Ga-DOTATOC as Preferred PET Imaging Tracer in Well-Differentiated Neuroendocrine Neoplasms.
    Veenstra EB; de Groot DJA; Brouwers AH; Walenkamp AME; Noordzij W
    Clin Nucl Med; 2021 Mar; 46(3):195-200. PubMed ID: 33323729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Combined Interpretation of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Classification System With Prognostic Impact.
    Hayes AR; Furtado O'Mahony L; Quigley AM; Gnanasegaran G; Caplin ME; Navalkissoor S; Toumpanakis C
    Clin Nucl Med; 2022 Jan; 47(1):26-35. PubMed ID: 34874347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Well-differentiated gastro-entero-pancreatic neuroendocrine tumors with positive FDG-PET/CT: a retrospective chart review.
    Haidar M; Al Mahmasani L; Chehade L; Elias C; El Jebai M; Temraz S; Charafeddine M; Al Darazi M; Shamseddine A
    Nucl Med Commun; 2023 Jun; 44(6):471-479. PubMed ID: 36897058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional imaging in neuroendocrine tumors: assessment of molecular heterogeneity using [
    Nogareda Seoane Z; Mallón Araújo MC; Calatayud Cubes A; Barberán Corral C; Domínguez Novoa Y; Cousillas Castiñeira A; Martínez Lago N; de Matías Leralta JM; Pubul Nuñez V
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2024; 43(3):500011. PubMed ID: 38643835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
    Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
    Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Value of
    Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
    J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.